Eli Lilly and Co
(NEOE:LLY)
C$
30.07
-0.05 (-0.17%)
Market Cap: 1.06 Tn
Enterprise Value: 1.10 Tn
PE Ratio: 87.15
PB Ratio: 50.94
GF Score: 68/100 
Eli Lilly and Co at Citi BioPharma Conference Transcript
Sep 07, 2022 / 07:30PM GMT
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
So good afternoon. Welcome back. Delighted to introduce our session. We have from Lilly, Dan Skovronsky, the CSO, CMO and President of Lilly R&D. Did I get that right?
Daniel M. Skovronsky
Eli Lilly and Company - Senior VP, Chief Scientific & Medical Officer and President of Lilly Research Labs
Yes, perfect.
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
All 3, excellent. I'm doing well. So we have about 40 minutes. I'd like to make this session interactive. Lilly currently enjoys by far the highest multiple of the group, which I'm sure everyone in this room knows.
Questions & Answers
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
Maybe just to kick off on donanemab, which is a program. We obviously have lecanemab data upcoming. We have the data from
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers